MedtechLedger currently links 130 FDA records to the applicant name Medtronic Neuromodulation. It includes 4 original PMA approvals. 28 entries are PMA supplements. 98 entries are 30-day notices. These are records held by this publication, rather than a count of the company’s entire portfolio.
The dated entries run from Nov 30, 1984 to Oct 30, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.
Device categories in this collection
Stimulator, Spinal-Cord, Totally Implanted For Pain Relief; Stimulator, Electrical, Implantable, For Incontinence; Implanted Electrical Device Intended For Treatment Of Fecal Incontinence; Stimulator, Tibial, Electrical, Implantable, For Urinary Incontinence.
Changes described in PMA records
FDA recorded decision OK30 on October 30, 2026 for Medtronic Neuromodulation's P840001/S636. This 30-Day Notice concerns production changes: an additional surface mount technology (SMT) line, a revised manufacturing sequence, and inspection and de-paneling equipment for printed circuit board assembly production. The database places the entry under process changes involving a manufacturer, sterilizer, packager or supplier.
The statement specifies that automated optical inspection will occur immediately after each SMT assembly stage. It also describes an equivalent solder paste inspection system and a qualified de-paneling machine. These are the particular factory steps and equipment identified in this notice. The record does not supply machine specifications, inspection acceptance limits, validation results or the full production procedure. It identifies product code LGW and the Neurology specialty, but provides no separate clinical findings for these manufacturing changes.
FDA approval-order wording
approval for the following three changes: 1) Adding a new surface mount technology (SMT) production line.2) Revision of the SMT manufacturing process sequence to perform automated optical inspection immediately following each SMT assembly stage.3) Addition of an equivalent solder paste inspection system and addition of a qualified de-paneling machine for PCBA production
Oct 30, 2026 · 30-Day NoticeThe FDA recorded decision OK30 on 2026-10-29 for PMA supplement P970004/S460, submitted by Medtronic Neuromodulation as a 30-Day Notice for a process change affecting manufacturing, sterilization, packaging or supplier operations. The supplement sits under P970004, whose listed title covers the InterStim Therapy System and Verify Evaluation System, including the SNS Urinary Neurostimulator 97800. The device category is an electrical implantable stimulator for incontinence, with gastroenterology and urology specialties and product code EZW.
The recorded statement describes battery-line process controls rather than a new approval of the whole system: enhanced operator verification of the FactoryWorks step and recorded battery pre-weight, pre- and post-weight out-of-control action plans, software and human machine interface updates that reject batteries above the established final-fill reasonable limit, dedicated white work-in-progress trays, an isopropyl alcohol wipe for residual electrolyte, and removal of Ball Press and Button Press certification prerequisites for ram changes on Medium Rate Line 2, with supervisors and engineers retaining certification responsibility. No documents were provided, so the underlying supplement filing and any clinical or labeling effect remain unknown.
The listed date is in the future relative to typical publication timelines, and the source does not state whether the notice was accepted without further review or what follow-up applies. Whether these manufacturing changes alter device performance or labeling cannot be determined from the record.
FDA approval-order wording
1. Enhanced operator verification of the applicable FactoryWorks processing step and recorded battery pre-weight.2. Addition of pre-weight and post-weight out-of-control action plans to the applicable Process Operation Descriptions.3. Software and Human Machine Interface updates that will automatically reject batteries with fill weights above the established final-fill reasonable limit.4. Introduction of dedicated white work-in-progress trays to distinguish electrolyte-filled batteries and improve line clearance, handling, and traceability.5. Use of an isopropyl alcohol wipe to remove residual electrolyte from battery surfaces before subsequent processing.6. Removal of the Ball Press and Button Press certification prerequisites from the Ball and Button Press Ram Change procedure, allowing Medium Rate Line 2 operators to qualify for press ram changes by completing only the ram-change procedure while supervisors and engineers retain responsibility for operator certification
Oct 29, 2026 · 30-Day NoticeFDA posted a 30-day notice for supplement S354 to PMA P080025, submitted by Medtronic Neuromodulation for the InterStim Therapy System and Verify Evaluation System. The supplement reason is a process change involving the manufacturer, sterilizer, packager, or supplier. The decision field records OK30, and the product code is QON for an implanted electrical device intended for treatment of fecal incontinence.
The statement lists six manufacturing changes: enhanced operator verification of a FactoryWorks processing step and recorded battery pre-weight; addition of pre-weight and post-weight out-of-control action plans to Process Operation Descriptions; software and human machine interface updates that automatically reject batteries above the final-fill reasonable limit; dedicated white work-in-progress trays for electrolyte-filled batteries; an isopropyl alcohol wipe to remove residual electrolyte; and removal of Ball Press and Button Press certification prerequisites from the ram-change procedure, with supervisors and engineers retaining responsibility for operator certification. The notice does not establish safety or clinical effectiveness.
FDA approval-order wording
1. Enhanced operator verification of the applicable FactoryWorks processing step and recorded battery pre-weight.2. Addition of pre-weight and post-weight out-of-control action plans to the applicable Process Operation Descriptions.3. Software and Human Machine Interface updates that will automatically reject batteries with fill weights above the established final-fill reasonable limit.4. Introduction of dedicated white work-in-progress trays to distinguish electrolyte-filled batteries and improve line clearance, handling, and traceability.5. Use of an isopropyl alcohol wipe to remove residual electrolyte from battery surfaces before subsequent processing.6. Removal of the Ball Press and Button Press certification prerequisites from the Ball and Button Press Ram Change procedure, allowing Medium Rate Line 2 operators to qualify for press ram changes by completing only the ram-change procedure while supervisors and engineers retain responsibility for operator certification
Oct 29, 2026 · 30-Day NoticeFDA posted a 30-day notice for PMA supplement S635 to P840001, covering Medtronic Neuromodulation spinal cord stimulation systems and leads. The dated statement lists six manufacturing process changes: enhanced operator verification of a FactoryWorks processing step and recorded battery pre-weight; addition of pre-weight and post-weight out-of-control action plans to Process Operation Descriptions; software and human machine interface updates that automatically reject batteries with fill weights above the established final-fill reasonable limit; introduction of dedicated white work-in-progress trays to distinguish electrolyte-filled batteries; use of an isopropyl alcohol wipe to remove residual electrolyte from battery surfaces; and removal of Ball Press and Button Press certification prerequisites from the ram change procedure.
The notice is a process change supplement, not a new approval of the whole system or an original PMA. The statement reports the intended purpose of the changes, such as improving line clearance, handling, and traceability, but does not independently establish safety or clinical effectiveness. No clinical indication, trial data, or benefit assessment is included. The source does not state whether these changes affect device labeling or performance specifications.
FDA approval-order wording
1. Enhanced operator verification of the applicable FactoryWorks processing step and recorded battery pre-weight.2. Addition of pre-weight and post-weight out-of-control action plans to the applicable Process Operation Descriptions.3. Software and Human Machine Interface updates that will automatically reject batteries with fill weights above the established final-fill reasonable limit.4. Introduction of dedicated white work-in-progress trays to distinguish electrolyte-filled batteries and improve line clearance, handling, and traceability.5. Use of an isopropyl alcohol wipe to remove residual electrolyte from battery surfaces before subsequent processing.6. Removal of the Ball Press and Button Press certification prerequisites from the Ball and Button Press Ram Change procedure, allowing Medium Rate Line 2 operators to qualify for press ram changes by completing only the ram-change procedure while supervisors and engineers retain responsibility for operator certification
Oct 29, 2026 · 30-Day NoticeThe FDA record P970004/S459, decided 2026-10-09 as OK30 under a 30-Day Notice for a process change involving a manufacturer, sterilizer, packager, or supplier, covers the InterStim Therapy System and Verify Evaluation System. The stated purpose is approval to introduce a second Medium Rate (MR) Header manufacturing line, MR Line 2, and to make inspection updates to the MR Headers Line currently in production at Medtronic Energy and Components Center (MECC), Brooklyn Center, MN. The applicant is Medtronic Neuromodulation; the device category is an electrical implantable stimulator for incontinence, product code EZW.
This is a supplement to PMA P970004, not a new approval of the whole system, and the notice concerns manufacturing and inspection at one site. The record does not describe header specifications, the inspection changes, validation data, or any clinical or safety finding; the stated purpose alone does not establish safety or effectiveness.
FDA approval-order wording
approval for the introduction of a second Medium Rate (MR) Headers manufacturing line (MR Line 2) and to make inspection updates to the MR Headers Line that is currently in production at Medtronic Energy and Components Center (MECC), Brooklyn Center, MN.
Oct 9, 2026 · 30-Day NoticeSubsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.